CD1a-Targeting CAR T-Cells for Cortical T-ALL Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for T-cell acute lymphoblastic leukemia (T-ALL) are limited, with intensive chemotherapy regimens offering less than 70% event-free and overall survival, and no curative options beyond hematopoietic cell transplantation and conventional chemotherapy, which are associated with significant toxicities.
Innovation Solution
Development of chimeric antigen receptor (CAR) T-cells specifically targeting CD1a, a lipid-presenting molecule expressed on cortical T-ALL cells, to selectively eliminate cancer cells while minimizing fratricide and immunodeficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CAR T-cells target pan T-cell antigens (CD3, CD5, CD7), then T-ALL blasts are efficiently eliminated, but CARTs self-target and cause fratricide
Solution Approach 1:
The patent applies local quality by selecting CD1a as a target antigen that is locally expressed on cortical T-ALL cells but not on mature T-cells or hematopoietic progenitors. This spatially restricted expression pattern allows CARTs to selectively eliminate T-ALL blasts while sparing normal T-cells, thereby achieving high cytotoxicity against tumors while avoiding fratricide.
Solution Approach 2:
The patent segments the T-cell development population by targeting a specific subset (cortical T-ALL cells expressing CD1a) rather than all T-cells. This segmentation is achieved through the use of CD1a-specific CARs that distinguish cortical T-ALL cells from other T-cell populations based on their unique CD1a expression, enabling selective elimination of the malignant subset while preserving normal T-cell function.
2Reliability
If CAR T-cells target pan T-cell antigens, then T-ALL is treated, but T-cell aplasia and immunodeficiency occur
Solution Approach 1:
The patent applies local quality by selecting CD1a as a target antigen that is locally expressed on cortical T-ALL cells but not on mature T-cells or hematopoietic progenitors. This spatially restricted expression pattern allows CARTs to selectively eliminate T-ALL blasts while sparing normal T-cells, thereby achieving high cytotoxicity against tumors while avoiding fratricide.
3Productivity
If CD7 CARS are used to treat T-ALL, then tumor cells are eliminated, but on-target/off-tumor effects occur due to CD1a expression on cortical thymocytes
Solution Approach 1:
The patent applies local quality by selecting CD1a as a target antigen that is locally expressed on cortical T-ALL cells but not on mature T-cells or hematopoietic progenitors. This spatially restricted expression pattern allows CARTs to selectively eliminate T-ALL blasts while sparing normal T-cells, thereby achieving high cytotoxicity against tumors while avoiding fratricide.
Data Source
AI summary
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor T-cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CARTs fratricide. CD 1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD 1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD 1a during ontogeny, confining the risk of on-target/off-tumor toxicity. The present invention provides CARs comprising a CD 1a-targeting moiety which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.